Emergent Biosolutions, Inc. (EBS) Social Stream
EMERGENT BIOSOLUTIONS INC (EBS) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering EMERGENT BIOSOLUTIONS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-08 | 7 | $120 | $50 | $83.666 | $23.69 | 253.17% |
| 2021-11-10 | 7 | $120 | $50 | $80 | $23.69 | 237.7% |
| 2022-01-18 | 6 | $75 | $50 | $62.5 | $23.69 | 163.82% |
| 2022-02-25 | 6 | $77 | $55 | $66.4 | $23.69 | 180.29% |
| 2022-02-28 | 6 | $77 | $40 | $61 | $23.69 | 157.49% |
| 2022-03-09 | 6 | $77 | $40 | $60.8 | $23.69 | 156.65% |
| 2022-04-27 | 6 | $77 | $40 | $60.6 | $23.69 | 155.8% |
| 2022-05-02 | 6 | $77 | $30 | $56.6 | $23.69 | 138.92% |
| 2022-05-03 | 6 | $77 | $30 | $50.2 | $23.69 | 111.9% |
| 2022-05-04 | 6 | $77 | $30 | $48.166 | $23.69 | 103.32% |
| 2022-05-10 | 5 | $77 | $30 | $48.166 | $23.69 | 103.32% |
| 2022-06-06 | 5 | $66 | $30 | $46.333 | $23.69 | 95.58% |
| 2022-08-03 | 5 | $65 | $30 | $43 | $23.69 | 81.51% |
The Trend in the Analyst Price Target
EBS's average price target has moved down $48.14 over the prior 13 months.
Over the past 47 weeks, EBS's average upside potential has been 64.01%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-03-09 | 6 | 77 | 40 | 60.800 | 42.20 | 44.08% |
| 2022-05-02 | 6 | 77 | 30 | 56.600 | 33.78 | 67.55% |
| 2022-06-06 | 4 | 66 | 30 | 46.333 | 30.80 | 50.43% |
| 2022-06-06 | 5 | 66 | 30 | 46.333 | 30.80 | 50.43% |
| 2022-06-06 | 5 | 65 | 30 | 44.500 | 30.80 | 44.48% |
EBS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.2 | 2 | 0 | 3 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
Over the past 43 weeks, EBS's average broker recommendation rating improved by 0.18.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- EBS has a lower variance in analysts' estimates than -1124.02% of all US stocks.
- EBS has a higher upside potential (average analyst target price relative to current price) than 1220.47% of all US stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, EMERGENT BIOSOLUTIONS INC's average analyst price target is higher than 1180.23% of them.
- EBS has a greater number of analysts covering the stock than 561.56% of stocks in the mid market cap category.
Stocks similar to EMERGENT BIOSOLUTIONS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are DVAX, DCPH, and CYTK.
View All Top Stocks by Price Target
Is EBS a Buy, Hold or Sell? See the POWR Ratings now!